Paper28042471
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
Paoluzzi L and 6 others. Clin Sarcoma Res, 2016. Cited by 173 papers, by iCite.
Cite this record
ConductScience Library. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Papers, record 28042471. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28042471
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25705114 | Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. | Sarcoma | 2015 | https://conductscience.org/library/papers/25705114 | PubMed |
| 2 | 26330427 | New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/26330427 | PubMed |
| 3 | 22595799 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet | 2012 | https://conductscience.org/library/papers/22595799 | PubMed |
| 4 | 25975445 | Immunotherapeutic approaches to sarcoma. | Curr Treat Options Oncol | 2015 | https://conductscience.org/library/papers/25975445 | PubMed |
| 5 | 27148906 | Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/27148906 | PubMed |
| 6 | 24349382 | Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. | PLoS One | 2013 | https://conductscience.org/library/papers/24349382 | PubMed |
| 7 | 24378391 | WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. | Pathology | 2014 | https://conductscience.org/library/papers/24378391 | PubMed |
| 8 | 19901961 | Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. | Oncogene | 2010 | https://conductscience.org/library/papers/19901961 | PubMed |
| 9 | 20601955 | Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. | Nat Genet | 2010 | https://conductscience.org/library/papers/20601955 | PubMed |
| 10 | 27312065 | Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. | Mod Pathol | 2016 | https://conductscience.org/library/papers/27312065 | PubMed |
| 11 | 22573349 | Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22573349 | PubMed |
| 12 | 26678880 | Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. | Cancer Sci | 2016 | https://conductscience.org/library/papers/26678880 | PubMed |
| 13 | 26451318 | A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. | Oncoimmunology | 2015 | https://conductscience.org/library/papers/26451318 | PubMed |
| 14 | 26742998 | Cancer statistics, 2016. | CA Cancer J Clin | 2016 | https://conductscience.org/library/papers/26742998 | PubMed |
| 15 | 25540867 | Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. | Hum Pathol | 2015 | https://conductscience.org/library/papers/25540867 | PubMed |
Cited by131
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 173 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958422 | Tazemetostat combined PD-1 inhibitor achieving prolonged survival in primary proximal epithelioid sarcoma: a case report and review of the literature. | J Med Case Rep | 2026 | https://conductscience.org/library/papers/42958422 | PubMed |
| 42650028 | Epithelioid Sarcoma: A Review and Update. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42650028 | PubMed |
| 42525308 | Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42525308 | PubMed |
| 42322431 | Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42322431 | PubMed |
| 42172443 | The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42172443 | PubMed |
| 42147185 | Immune modulatory oncolytic virus for osteosarcoma therapy. | Res Sq | 2026 | https://conductscience.org/library/papers/42147185 | PubMed |
| 41964900 | PEComas: current concepts in diagnosis, molecular pathways, and emerging treatments. | Oncologist | 2026 | https://conductscience.org/library/papers/41964900 | PubMed |
| 41960153 | Integrative Oncology Approach in Advanced Myxofibrosarcoma: A Case Report of Prolonged Survival with High-Dose Vitamin C and Viscum album. | Case Rep Oncol | 2026 | https://conductscience.org/library/papers/41960153 | PubMed |
| 41752158 | Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41752158 | PubMed |
| 41630035 | A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas. | J Transl Med | 2026 | https://conductscience.org/library/papers/41630035 | PubMed |
| 41609192 | A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi-Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De-Differentiated Chondrosarcoma. | Cancer Rep (Hoboken) | 2026 | https://conductscience.org/library/papers/41609192 | PubMed |
| 41341391 | Spontaneous hepatic rupture: A catastrophic complication in a patient with primary splenic angiosarcoma and hepatic metastasis: case report and literature review. | Front Oncol | 2025 | https://conductscience.org/library/papers/41341391 | PubMed |
| 41294677 | Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41294677 | PubMed |
| 41131073 | Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/41131073 | PubMed |
| 40927310 | Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment. | J Immunother Precis Oncol | 2025 | https://conductscience.org/library/papers/40927310 | PubMed |
| 40867318 | Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40867318 | PubMed |
| 40465137 | Retroperitoneal Sarcoma (RPS): A Systematic Review. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/40465137 | PubMed |
| 40304333 | Identification and Experimental Validation of Tumor Antigens and Hypoxia Subtypes of Osteosarcoma for Potential mRNA Vaccine Development. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/40304333 | PubMed |
| 40184088 | CD274/PD-L1 copy number gained malignant peripheral nerve sheath tumor: A case report and literature review. | Medicine (Baltimore) | 2025 | https://conductscience.org/library/papers/40184088 | PubMed |
| 40117529 | Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/40117529 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PDCD1LG2 | 80380 | PubTator's text mining | https://conductscience.org/library/genes/80380 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28042471
GET https://conductscience.org/api/papers/v1/28042471/cited_by?page=2